Purpose: To review the diagnosis and management of gestational diabetes.
Introduction
In the United States, approximately 2 to 7% of all pregnant women have gestational diabetes mellitus (GDM). 1 However, challenges remain in caring for the pregnant patients with diabetes, particularly those with poor glycemic control. Thus, effective management of both the pregnancy and diabetes is essential. This article reviews current recommendations for the diagnosis and management of GDM.
Even in women without diabetes, pregnancy induces insulin resistance and reduced sensitivity to insulin action resulting from hormones produced by the placenta, in particular, human placental lactogen or human chorionic somatomammotropin as well as growth hormone and corticotropin releasing hormone. 2, 3 In women with marginal insulin secretory capacity, decreased insulin suppression of hepatic glucose production, and/or already impaired insulin sensitivity, a hyperglycemic syndrome resembling type 2 diabetes ensues GDM. 4, 5 As levels of the diabetogenic placental hormones increase with placental size, gestational diabetes is usually not present until well into the second or third trimester of pregnancy. Of note, because of increased placental mass, women with multiple gestations have both a higher risk of gestational diabetes and it may present earlier.
Gestational diabetes mellitus
Gestational diabetes mellitus is defined as glucose intolerance with the onset or first detection during pregnancy. 6, 7 Most commonly, it has been reported that gestational diabetes complicates approximately 5 to 7% of all pregnancies, thus accounting for more than 200 000 pregnancies annually in the United States. 1, 8 Major risk factors for developing GDM include increasing maternal age, family history of diabetes, history of GDM in a prior pregnancy, history of macrosomia and increased pregravid body mass index. 9 GDM is more common among Asian, Hispanic/Latina and native American women. 9 Although early studies demonstrated an increased risk among AfricanAmerican women, 10 these differences appeared to dissipate when confounders, such as obesity, were controlled for. 11 Gestational diabetes mellitus has been associated with increased maternal perinatal morbidity (resulting from increases in cesarean deliveries and forceps or vacuum extraction, as well as third-and fourth-degree perineal lacerations), principally through its association with fetal macrosomia. [12] [13] [14] Macrosomia is also associated with an increased risk of adverse neonatal outcomes, such as shoulder dystocia, brachial plexus injuries and clavicular fracture. 12, 15 Additionally, because of differences in biometrics, infants of pregnancies complicated by diabetes are at increased risk of shoulder dystocia when compared to infants with same birthweight but of pregnancies not complicated by diabetes. Such risk of shoulder dystocia is particularly present if fetal head-to-abdominal asymmetry is noted by sonographic estimates. 16 They appear to carry the same risk as an infant from a nondiabetic pregnancy who weighs 250 g more. 17 In addition to the adverse outcomes associated with macrosomia, women with gestational diabetes have a higher rate of developing preeclampsia. 18, 19 In pregnancies truly complicated by GDM, as opposed to pregestational diabetes, neonates should not have a higher risk of congenital anomalies. However, because of the metabolic effects of hyperglycemia in the third trimester, they do carry increased risk of hypoglycemia, respiratory distress syndrome, neonatal jaundice and hypocalcemia. 20, 21 Besides the immediate adverse neonatal outcomes associated with hyperglycemia in pregnancies complicated by unrecognized or poorly controlled gestational diabetes, long-term impact of GDM on early childhood and beyond is evident. The prevalence of metabolic syndrome, defined by the presence of obesity, hypertension, dyslipidemia and glucose intolerance, was evaluated in a longitudinal cohort of children from age 6 through 11. The prevalence of having three or more components of metabolic syndrome by age 11 was 15% for those children born large for gestational age in women with gestational diabetes, compared to 3.0 to 5.3% when born average for gestational age in women with or without GDM as well as large for gestational age without GDM. 22 Other studies have also validated that childhood obesity and impaired glucose tolerance is associated with increased birth weight, maternal obesity and gestational diabetes.
23-25
Screening for GDM The concept of screening for GDM in pregnant women using an oral glucose load was first introduced by O' 26,27 Although the original goal was to identify a subset of pregnant women at increased risk for developing type 2 diabetes later in life, it was observed that gestational diabetes may be associated with perinatal mortality. 28 Currently, the American College of Obstetricians and Gynecologists (ACOG) recommends that all pregnant women should be screened for GDM, either by clinical history or by laboratory testing. 6 Clinical screening involves the evaluation of patients' clinical history and risk factors and then administration of oral glucose challenge test only to those who are at increased risk. However, it has been reported that screening for GDM based on risk factors alone only captures approximately 50% of the cases of GDM, 29 and thus, most clinicians practice universal screening of prenatal patients. The 50 g oral glucose challenge test is the most commonly used laboratory screening modality for GDM in the United States. Depending on the screening threshold utilized, varying sensitivities can be achieved. For example, using 130 mg per 100 ml achieves a 99% sensitivity with a 22% screen-positive rate, whereas a 140 mg per 100 ml threshold achieves an 80% sensitivity with a 13% screen-positive rate. 6 While the ACOG advocates universal screening, the American Diabetes Association (ADA) recommends risk-based screening, with those at high risk of GDM (marked obesity, personal history of GDM, glycosuria, high-risk racial/ethnic groups or a strong family history of diabetes) receiving glucose challenge test as soon as feasible; those with average risk should be screened between 24 to 28 weeks gestation and those with low risk need not be tested. 8 To be considered 'low risk', a women has to meet all of these characteristics: age <25 years, weight normal before pregnancy, members of an ethnic group with a low prevalence of GDM, no known diabetes in first-degree relatives, no history of abnormal glucose tolerance and no history of poor obstetric outcomes. 8, 30 In 1999, a study demonstrated that if only pregnant patients meeting these ADA criteria were screened, 97% of GDM would be diagnosed. However, only 10% of patients would go unscreened. 31 In another study that directly compared the detection rate and false-positive rate of universal versus risk-based screening using a complex screening strategy in which risk scores for GDM were assigned based on age, body mass index, and race, the detection rate of GDM remained approximately 80% for both strategies with a minimal reduction in false-positive rate using the complex algorithm of selective screening that may be impractical in clinical setting. 32 Although the US Preventive Services Task Force indicates that better quality evidence is needed to support universal screening, 33 currently 94% of providers in the United States screen all pregnant women. 34 Whereas the selective screening may be appropriate for a population with a low prevalence of GDM, a 2001 Practice Bulletin from the ACOG notes that only a small percentage of patients meet criteria as low risk in the United States. Thus, universal screening using 50 g 1-h glucose loading test (GLT) may be a more practical approach. 6 Establishing a threshold for further confirmatory testing of GDM has been a matter of some controversy. Coustan et al. 35 demonstrated that by using the 50-g 1-h GLT with a threshold of 140 mg per 100 ml, only 80% of GDM would be diagnosed, with a 13% screen-positive rate. However, if a threshold of 135 mg per 100 ml is used, 98% of GDM is diagnosed, but up to one in five patients will be subjected to the 3-h test. 33 Near 100% sensitivity can be achieved utilizing a screen of 130 mg 100 ml, but this would be with 22% of individuals having a positive screening test.
Another area of controversy is whether the same screening test should be used for all patients. One recent study that examined the screening test properties of the 50 g 1-h glucose challenge test for GDM among various ethnic groups found that the testing characteristics varied among women from different races/ ethnicities (Table 1) . 36 For example, if the goal was to achieve a 95% sensitivity, a screen-positive threshold of 135 mg per 100 ml could be used among African-American women, but 132 or 133 mg per 100 ml would be used in other ethnicities. If the goal was to keep false positives to <10%, 140 mg per 100 ml would be an adequate threshold for Caucasians, 135 mg per 100 ml for African Americans, but the threshold would need to be higher for Latinas and Asians. 36 One question that clinicians often encounter is whether there exists a threshold of GLT high enough that the diagnosis of GDM can be assumed without performing the 3-h glucose tolerance test (GTT). Despite a markedly elevated 1-h GLT >180 or >200 mg per 100 ml, nearly one in five women may still be ruled out for GDM with a negative 100 g 3-h oral GTT. However, these women have been demonstrated to experience worse perinatal outcomes. 37, 38 Perhaps, the more important question becomes 'who is at risk' for perinatal morbidity, and treating women with a markedly elevated GLT as if they have a diagnosis of GDM without further administration of the confirmatory 3-h GTT may actually lead to better outcomes.
Diagnosis of GDM
Gestational diabetes mellitus can be diagnosed with a fasting blood glucose of 126 mg per 100 ml and greater or a random blood glucose of 200 mg per 100 ml and greater, similar to type 2 diabetes mellitus. 8, 30 Outside the United States, a 75 g 2-h GTT is widely used, with two different diagnostic criteria established by the ADA as well as the World Health Organization (Table 2) . 8, 39 Despite the differences in diagnostic criteria established by the ADA or the World Health Organization, however, both are able to identify women at risk of complications associated with GDM. 40 In the United Sates, the 100 g 3-h oral GTT is often used following a positive screening test. Two different diagnostic criteria were established, the Carpenter/Coustan (based on venous plasma glucose values) and the more stringent National Diabetes Data Group (NDDG) thresholds (based on whole blood; Table 3 ). 6, 41 The ADA and various experts on GDM both recommend using the more inclusive Carpenter/Coustan diagnostic criteria for the diagnosis of GDM. 30, 42 As the Carpenter/Coustan criteria are more inclusive, it captures more of the women at risk for perinatal complications associated with GDM. 43 To examine whether the 100 g 3-h GTT could be simplified by omitting the third-hour value, two studies report the sensitivity of the 3-h GTT was reduced to approximately 90%, misclassifying some women with GDM as normal glucose tolerance. 37, 44 What about those women with a positive GLT who subsequently ruled out for GDM? Are they truly risk-free? Two recent studies found that women with an abnormal GLT but negative GTT still had higher risk of preeclampsia, cesarean delivery, macrosomia, shoulder dystocia, and neonatal morbidities that are often associated with poor glycemic control. 45, 46 As Carpenter and Coustan so eloquently stated, the relationship between carbohydrate intolerance and adverse perinatal outcome is a continuous one, and no single cutoff can truly separate those at high risk and those at no risk at all. 47 Thus, the cost of screening and diagnosis of GDM must be weighed against the benefits of treatment to achieve optimal perinatal outcomes for women with or at risk for GDM.
Management of GDM
The initial management of women with GDM includes education, diet modifications, light exercise, and assessment of plasma glucose with self-monitored blood glucose measurements. The glucose levels should be assessed four times a day (fasting and postprandial) with the goal of maintaining glycemic levels <95 mg per 100 ml in the fasting state and <140 mg per 100 ml when 1-h postprandial. 48 Of note, some clinicians utilize 2-h postprandial evaluations with a goal of <120 mg per 100 ml. 49, 50 Carbohydrate counting is an important component of management and should be utilized to obtain a daily Utilizing a combination of these management schemes has been demonstrated to reduce maternal and neonatal morbidity, even in GDM patients with mild insulin resistance. 51 In addition, an ultrasound examination at 36 weeks gestation for an estimated fetal weight (EFW) may be obtained. Depending on these findings in women who have not required medical intervention with insulin or oral agents, commonly, such pregnancies are managed expectantly until the due date. With a finding of impending macrosomia, some clinicians will offer induction of labor. Whereas such an intervention has not been shown to change the risk of cesarean delivery, earlier induction has been associated with lower birth weight. 52 If diet and exercise fail to maintain self-monitored glycemia at <95 mg per 100 ml (fasting plasma glucose) and <140 mg per 100 ml (1 h postprandial), standard of care is to initiate subcutaneous insulin therapy. Free insulin does not cross the placenta, therefore, no particular risks of such therapy need to be considered other than accidental insulin overdose leading to maternal hypoglycemia. 6 In fact, patients can be counseled that the glucose does cross the placenta leading to metabolic problems in the fetus and neonate, which is precisely what is being prevented by insulin therapy. There is no particular data comparing the efficacy of the multitude of feasible insulin regimens. Most commonly, we utilize neutral protamine hagedorn (NPH) insulin at bedtime to control elevated fasting blood glucose values and fasting acting humalog (Lispro) insulin to control breakfast and dinner hyperglycemia. For lunchtime hyperglycemia, either a pre-lunch humalog insulin dose can be used or a dose of NPH insulin given at the same time as the prebreakfast humalog insulin dose. The former carries no risk of mid-morning hypoglycemia, but lacks the convenience of not having to give a midday injection.
Regular insulin, which has a 30 min onset of action that peaks at approximately 2 h, is less efficient in the management of diabetes mellitus. Particularly in gestational diabetes, regular insulin should not be used as it is quite onerous to schedule injections precisely before meal times. Glargine insulin, which has an attractive serum profile, one that lacks a peak, has little safety data in pregnancy in women with gestational diabetes, limited to one case report of four patients. 53 As many gestational diabetics will have primarily problems with postprandial hyperglycemia, such insulin probably has only a small role at best in most patients with gestational diabetes. However, for those women who also require basal insulin, glargine insulin may lead to better control throughout the day with less hypoglycemia.
Use of oral agents contraindicated
The use of oral hypoglycemic agents in GDM should still be considered investigational as there has not been overwhelming confirmatory evidence that these agents are either as safe or even lead to the same level of glycemic control as insulin. While insulin administration may be time consuming and requires teaching of insulin injections, oral hypoglycemic agents offer the convenience of ease-of-use, which may improve compliance. Whereas oral hypoglycemic agents generally have not been used during pregnancy due to concerns of teratogenicity and potential neonatal hypoglycemia associated with their use, studies have shown that newer generation sulfonylurea crosses the placenta in trace amount and may be safe during pregnancy. 54, 55 A study by Langer et al. 56 compared glyburide with conventional insulin therapy in 404 patients with GDM and found that there was 'no difference' in neonatal outcomes. However, the study was underpowered to demonstrate a difference between these two groups and actually demonstrated a trend toward an increase in neonatal complications in the glyburide-treated group. Since the initial study, several subsequent retrospective studies have further investigated the use of glyburide in GDM. The most recent and largest was a study of 584 women reported by Jacobson et al. 57 The study compared women initially managed with insulin versus glyburide. Whereas the study demonstrated no differences in neonatal birth weight, it did report higher rates of preeclampsia and higher rates of phototherapy use in the neonates delivered in the glyburide group. Another recent study found higher rates of macrosomia and neonatal hypoglycemia in the neonates whose mothers were treated with glyburide. 58 Further, it appears that approximately 20% of women treated with glyburide will fail this management resulting in less time to optimally achieve control with insulin. 56, 59, 60 Given the lack of further confirmation on the findings regarding the safety and efficacy of glyburide by large, randomized controlled studies and the limitations of observational studies, the ACOG has designated the use of glyburide in pregnancy to be experimental. 6 Thus, awaiting further evidence on the efficacy of glyburide, its use for the current treatment of GDM should not be routine. Additionally, experts recommend that metformin should be avoided during pregnancy as it does cross the placenta and its use in pregnancy has not been well studied. 48,61 -63 Again, the use of oral hypoglycemia agents in pregnancy should be considered experimental and reserved for research protocols in which women undergo formal informed consent. At our institution, the ability of all women with A2 GDM to self-administer insulin is assessed. We have found that the vast majority of women, even those with poor education, lower socioeconomic status, or who do not speak English are able to safely and adequately utilize insulin to control their blood glucose levels. However, in women who are homeless, with otherwise unstable housing and social situations, or simply too needle-phobic to safely store and inject insulin, we will suggest beginning glycemic management with glyburide. In this setting, these women are counseled regarding the investigational nature of the medication and why it might be a reasonable mode of treatment to start with in their particular case.
Antepartum pregnancy management
The protocol at our institution calls for management of A2 GDM patients, those requiring medical therapy, similar to the management of patients with pregestational type 2 diabetes. Antenatal testing is initiated starting at 32 weeks and induction of labor scheduled at 39 weeks of gestation. As women with A1 GDM, those on diet control only, without other pregnancy complications are presumed to have satisfactory glycemic control and thus not at risk for complications associated with persistent hyperglycemia, antenatal testing is initiated at 40 weeks and delivery is recommended by 41 weeks. Again, this is based on the ability to maintain adequate glycemic control and a normal EFW on ultrasound obtained at 36 weeks of gestation. There is only one prospective randomized trial in such women that demonstrated no difference in cesarean delivery, but less macrosomia, in women induced at 38 to 39 weeks of gestation. 64 Thus, we have utilized this protocol to guide our counseling of women with respect to the risks and benefits of induction of labor versus expectant management of the pregnancy in this setting.
Labor and delivery
Insulin requirements usually decrease during labor as the patient may be fasting and exerting significant energy. A1 GDM patients who have not required medical therapy in their pregnancy rarely require insulin during labor and delivery, unless they were simply noncompliant and had undiagnosed A2 GDM. For women with A2 GDM, an insulin infusion during labor and delivery is commonly used to maintain tight regulation of plasma glucose. A sample regimen for a patient with A2 GDM is shown in Table 4 . In general, during labor, blood glucose values through self-monitored blood glucose measurements are checked every 2 h and if the values rise above 120 mg per 100 ml, an insulin drip is begun.
When labor is induced in the morning, A2 GDM diabetic patients can take their NPH insulin the prior night. If labor is induced with prostaglandins, they may take their usual NPH insulin dose in the morning. If labor is induced with oxytocin, they should skip the morning NPH dose. The reason for this is that when in active labor, having a long-acting insulin on board can lead to hypoglycemia, which can be much harder to correct than hyperglycemia. Thus, if uncertain, it is usually better to hold longacting insulin in favor of using an insulin drip. In the setting of a cesarean delivery, patients may take their usual dose of NPH insulin in the prior evening, but nothing by mouth and no insulin after midnight.
Postpartum management
Women who experience GDM, particularly those who are overweight, have a 50% lifetime risk for developing type 2 diabetes.
65 Risk factors include obesity, gestational age at diagnosis of GDM and the degree of abnormality of postpartum glucose tests. Patients determined to be at risk should be counseled regarding diet, exercise and weight reduction to delay or prevent the onset of type 2 diabetes. 8 Owing to the high risk of type 2 diabetes in GDM patients, diagnostic testing for diabetes is appropriate at the time of the 6-week postpartum visit. 6 It is unclear whether the traditional 75 g 2-h oral glucose challenge test or simply a fasting serum glucose may be more useful at this time. Whereas the oral glucose challenge test may identify more patients with abnormal carbohydrate tolerance, it is uncertain that such a test has added benefit. 66 As the ADA is currently using fasting glucose >125 mg per 100 ml to define type 2 diabetes, and values between 95 and 125 mg per 100 ml to indicate a 'pre-diabetic' condition, this is the test we recommend. Of note, the ACOG indicates that there may be advantages in performing the oral GTT as the initial diagnostic test after pregnancy complicated by GDM. 6 Again, it is not entirely clear what these advantages are other than reinforcing the idea that these women are at increased risk for eventually developing type 2 diabetes.
Elective cesarean
There is much debate over whether elective cesarean delivery should be employed in the setting of pregestational or gestational diabetes for the prevention of birth trauma, specifically shoulder dystocia and brachial plexus injury. Of note, it has been estimated that with a threshold of 4500 g in diabetic patients, 443 cesarean would need to be performed to prevent one brachial plexus injury. 67 Whether this trade-off is worth the increased risks of cesarean delivery is unclear. The most recent ACOG bulletin on the topic of macrosomia suggests that in women without diabetes, an elective cesarean is reasonable with an EFW at 5000 g or above.
68,69 However, they are less clear about what to do in the setting of macrosomia and diabetes. If one were to utilize the information that a diabetic patient has an equal risk of shoulder dystocia in a nondiabetic patient with a birth weight of 250 g higher, then it seems reasonable to offer an elective cesarean with an EFW of 4750 g or higher. In the technical bulletin itself, ACOG states that a prophylactic cesarean 'may be considered' in diabetic patients with an EFW of 5000 g or above. This is not a ringing endorsement of such a practice pattern, and it is important to stress the impact of the prophylactic cesarean not only on the current pregnancy, but on all future pregnancies as well.
At our institution, we offer, but do not recommend, a cesarean with an EFW of 4500 g or above. In our counseling, we address the following issues: (1) problems with predicting birth weight using obstetric ultrasound; (2) the risks of a cesarean delivery in the current pregnancy including increased bleeding, wound infection and prolonged recovery time and (3) the risks of a trial of labor in future pregnancies as well as the increased risk of placenta previa, accrete and even hysterectomy with multiple cesareans. If a woman with an EFW of 4500 g or greater decides to undergo a trial of labor, we follow the labor curve closely and perform operative vaginal deliveries only if the fetal vertex has descended normally in the second stage of labor.
Areas for future research
In the future, hopefully larger randomized controlled studies will be conducted to examine the efficacy of glyburide and other oral agents such as metformin. Such studies will need to avoid the prior problems of lack of statistical power and type 2 error. Although it is common that most institutions utilize universal screening, future research is also necessary to examine whether there are low-risk populations that may not require screening. Further, such risk examination should also determine which groups of women (stratified by age, race/ethnicity, body mass index and family history) will benefit from diabetes screening early in pregnancy. Prospective cohort studies designed to follow-up both women and neonates after pregnancies complicated by diabetes may also help to characterize the long-term medical issues in women and their children. Finally, examination of both the screening test and diagnostic test thresholds to make certain that all of the higher risk women are identified with respect to carbohydrate intolerance should continue with larger, multicenter studies powered to identify differences in more severe neonatal morbidities.
Regarding technological advances, studies of inhaled insulin have been conducted and this may become a marketed reality in the very near future. 70 Continuous glucose monitoring systems are currently used by some patients with type 1 diabetes, and it remains to be seen whether their use will improve glycemic control. Meters capable of beaming information to pumps and regulating insulin injections are being developed. On the surgical front, pancreatic transplantation continues to be investigated. 71 However, short-term survival is reported to better with the use of exogenous insulin. 72 
Conclusion
It is clear that GDM does appear to carry increased risk of perinatal complications to both the parturient and her fetus/neonate. Such risks appear to be reduced by glycemic control, which can be accomplished with diet, exercise or pharmaceutical intervention. The evolution of technologies and clinical knowledge has made it possible for such patients to experience pregnancies similar to those of the normal population, but patient management can be clinically challenging. Further advances in the near future are likely to offer physicians and patients more options for achieving optimal outcomes.
